Tags

Type your tag names separated by a space and hit enter

Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran.
J Infect Public Health. 2013 Apr; 6(2):120-4.JI

Abstract

Glucantime remains the first-line treatment for cutaneous leishmaniasis. In a prospective study, we evaluated its efficacy and side effects in patients treated in Yazd from 2010 to 2011.

METHODS

Patients with lesions compatible with cutaneous leishmaniasis were considered eligible for inclusion in this study if the disease was confirmed parasitologically. The exclusion criteria were as follows: the patient preferred a treatment modality other than Glucantime; there was no indication for treatment; the patient had underlying kidney, liver, or cardiac disease; or was pregnant and lactating. Patients with ≤3 lesions and/or lesions <3cm in diameter were treated with Glucantime intralesionally if the lesions were not located on the face, neck or joints; sporotrichoid; or superinfected with bacteria. All other patients were prescribed intramuscular Glucantime at 10-20mg/kg/day for 20 days.

RESULTS

The failure rate for patients treated with one course of Glucantime was 22.6% overall. There were no associations between age, sex, weight, the route of administration, the number and size of lesions, the adequacy of the dose of the drug injected intramuscularly, the number of intralesional injections (<6 or ≥6) and the duration of therapy. The only factor associated with failure was reported previous exposure to antimony (p value 0.047). Adverse effects occurred in 14.2% of patients (22/155).

CONCLUSION

Glucantime is an effective drug for the treatment of cutaneous leishmaniasis in central Iran. However, because cutaneous leishmaniasis heals spontaneously and to prevent the acquisition of resistance, the indications for treatment in each region should be defined carefully.

Authors+Show Affiliations

Shahid Sadoughi University of Medical Sciences, Yazd, Iran. mahmoudmohammadzadeh@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23537825

Citation

Mohammadzadeh, Mahmoud, et al. "Efficacy of Glucantime for Treatment of Cutaneous Leishmaniasis in Central Iran." Journal of Infection and Public Health, vol. 6, no. 2, 2013, pp. 120-4.
Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. J Infect Public Health. 2013;6(2):120-4.
Mohammadzadeh, M., Behnaz, F., & Golshan, Z. (2013). Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. Journal of Infection and Public Health, 6(2), 120-4. https://doi.org/10.1016/j.jiph.2012.11.003
Mohammadzadeh M, Behnaz F, Golshan Z. Efficacy of Glucantime for Treatment of Cutaneous Leishmaniasis in Central Iran. J Infect Public Health. 2013;6(2):120-4. PubMed PMID: 23537825.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. AU - Mohammadzadeh,Mahmoud, AU - Behnaz,Fatemah, AU - Golshan,Zahra, Y1 - 2013/02/01/ PY - 2012/05/10/received PY - 2012/10/25/revised PY - 2012/11/07/accepted PY - 2013/3/30/entrez PY - 2013/3/30/pubmed PY - 2013/9/24/medline SP - 120 EP - 4 JF - Journal of infection and public health JO - J Infect Public Health VL - 6 IS - 2 N2 - UNLABELLED: Glucantime remains the first-line treatment for cutaneous leishmaniasis. In a prospective study, we evaluated its efficacy and side effects in patients treated in Yazd from 2010 to 2011. METHODS: Patients with lesions compatible with cutaneous leishmaniasis were considered eligible for inclusion in this study if the disease was confirmed parasitologically. The exclusion criteria were as follows: the patient preferred a treatment modality other than Glucantime; there was no indication for treatment; the patient had underlying kidney, liver, or cardiac disease; or was pregnant and lactating. Patients with ≤3 lesions and/or lesions <3cm in diameter were treated with Glucantime intralesionally if the lesions were not located on the face, neck or joints; sporotrichoid; or superinfected with bacteria. All other patients were prescribed intramuscular Glucantime at 10-20mg/kg/day for 20 days. RESULTS: The failure rate for patients treated with one course of Glucantime was 22.6% overall. There were no associations between age, sex, weight, the route of administration, the number and size of lesions, the adequacy of the dose of the drug injected intramuscularly, the number of intralesional injections (<6 or ≥6) and the duration of therapy. The only factor associated with failure was reported previous exposure to antimony (p value 0.047). Adverse effects occurred in 14.2% of patients (22/155). CONCLUSION: Glucantime is an effective drug for the treatment of cutaneous leishmaniasis in central Iran. However, because cutaneous leishmaniasis heals spontaneously and to prevent the acquisition of resistance, the indications for treatment in each region should be defined carefully. SN - 1876-035X UR - https://www.unboundmedicine.com/medline/citation/23537825/Efficacy_of_glucantime_for_treatment_of_cutaneous_leishmaniasis_in_Central_Iran_ DB - PRIME DP - Unbound Medicine ER -